z-logo
Premium
Dipeptidyl peptidase‐ IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database
Author(s) -
García M.,
Aranburu M. A.,
PalaciosZabalza I.,
Lertxundi U.,
Aguirre C.
Publication year - 2016
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12397
Subject(s) - bullous pemphigoid , vildagliptin , medicine , pharmacovigilance , alogliptin , pemphigoid , metformin , dermatology , linagliptin , saxagliptin , dipeptidyl peptidase 4 , dipeptidyl peptidase 4 inhibitor , pharmacology , sitagliptin , diabetes mellitus , drug , endocrinology , immunology , type 2 diabetes mellitus , type 2 diabetes , antibody
Summary What is known and objective Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance. Case summary A 74‐year‐old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal. What is new and conclusion A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here